Lipodom's mission is the development of diagnostic products to prevent and detect human diseases that presently lack proper and painless diagnosis, effective therapy or are viewed as untreatable. We wish to exploit the unique properties of these methods to develop effective tools for neurodegenerative (Alzheimer's, Parkinson's, ALS), cancer and metabolic diseases (diabetes and its complications, lipid storage diseases).
Chemist, physicist, medical doctors and engineers established Lipodom Analytics with the competency of managing development projects. We have the ability of planning, designing, implementing and exploiting CLINGLIO project by the knowledge of PMI standards in project management, massive experience on mass spectrometry and general medicine, clinical research and marketing with sales operations.
The strategic aim of Lipodom Analytics is to provide novel lipidomics service for academic and industrial partners. We perform lipidomics by high-resolution shotgun mass spectrometry and can identify and quantify hundreds of phospholipid, sphingolipid and glycolipid species from sub-milligram amount (wet weight) of human and animal samples.